Australian Bureau of Statistics. Prisoners in Australia. Cat. no. 4517. Canberra: Australian Bureau of Statistics, 2013.
Teutsch, S, et al.
Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health
2010; 10: 633.
Hepatitis B vaccination: The key towards elimination and eradication of hepatitis B. Journal of Hepatology
2009; 50: 805–16.
Australian Government Department of Health and Ageing. The Australian Immunisation Handbook, 10th edn. Canberra: Australian Government Publishing Services, 2013.
Butler, T, et al. National Prison Entrants’ Bloodborne Virus and Risk Behaviour Survey Report 2004, 2007 & 2010. The Kirby Institute (University of New South Wales) and the National Drug Research Institute (Curtin University), 2011.
Gidding, H. Australia's national serosurveillance program. NSW Public Health Bulletin
2003; 14: 90–93.
Kelly, H, et al.
A random cluster survey and a convenience sample give comparable estimates of immunity to vaccine preventable diseases in children of school age in Victoria, Australia. Vaccine
2002; 20: 3130–3136.
Australian Bureau of Statistics. Prisoners in Australia. Cat. no. 4517. Canberra: Australian Bureau of Statistics, 2007.
Larney, S, et al.
A cross-sectional study of susceptibility to vaccine-preventable diseases among prison entrants in New South Wales. Medical Journal of Australia
2013; 198: 376–379.
Butler, T, Papanastasiou, C. National Prison Entrants’ Bloodborne Virus and Risk Behaviour Survey Report 2004 & 2007. National Drug Research Institute (Curtin University) and National Centre in HIV Epidemiology and Clinical Research (University of New South Wales), 2008.
Lohr, SL. Sampling: Design and Analysis. Pacific Grove: Duxbury; 1999.
Hennessey, KA, et al.
Prevalence of infection with hepatitis B and C viruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States. Journal of Urban Health
2009; 86: 93–105.
McQuillan, GM, et al.
Prevalence of hepatitis B virus infection in the United States: the National Health and Nutrition Examination Surveys, 1976 through 1994. American Journal of Public Health
1999; 89: 14–18.
Weild, AR, et al.
Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey. Communicable Disease & Public Health
2000; 3: 121–126.
Gay, NJ, et al.
The prevalence of hepatitis B infection in adults in England and Wales. Epidemiology and Infection
1999; 122: 133–138.
Harzke, AJ, et al.
Heterogeneity in hepatitis B virus (HBV) seroprevalence estimates from U.S. adult incarcerated populations. Annals of Epidemiology
2009; 19: 647–650.
Sutton, AJ, et al.
Modelling the impact of prison vaccination on hepatitis B transmission within the injecting drug user population of England and Wales. Vaccine
2006; 24: 2377–2386.
Hayashi, K, et al.
Incarceration experiences among a community-recruited sample of injection drug users in Bangkok, Thailand. BMC Public Health
2009; 9: 492.
Kenny, D, et al. NSW young people on community orders health survey 2003–2006: Key findings report. The University of Sydney, 2006.
Martire, KA, Larney, S. An estimate of the number of inmate separations from Australian prisons 2000/01 and 2005/06. Australian & New Zealand Journal of Public Health
2010; 34: 255–257.
Christensen, PB, et al.
Hepatitis B vaccination in prison with a 3-week schedule is more efficient than the standard 6-month schedule. Vaccine
2004; 22: 3897–3901.
But, DY, et al.
Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine
2008; 26: 6587–6591.
Reekie, JM, et al.
Trends in HIV, hepatitis B and hepatitis C prevalence among Australian prisoners – 2004, 2007, 2010. Medical Journal of Australia
2014; 200: 277–280.